Interim data from Dogwood Therapeutics’ ongoing Phase 2b HALT-CINP study point to a favorable operational and clinical signal: a 4.3% early termination rate among the first 116 patients completing the trial, an overall dropout rate near 4%, and unblinded committee review of 97 completers indicating separation from placebo in pain improvement over four weeks. The study is designed with greater than 80% power to detect a treatment difference at unblinding, and enrollment has passed the 50% mark. Topline readout is targeted for the third quarter of 2026.
The core update is enrollment progress and interim conduct metrics for Halneuron, a fast track–designated, non-opioid Nav1.7 modulator being tested in chemotherapy-induced neuropathic pain. HALT-CINP randomizes patients with established neuropathy following platinum- or taxane-based chemotherapy to eight subcutaneous doses over 14 days with 28 days of total follow-up. The primary endpoint is change from baseline to week four in the weekly average of daily 24-hour recall pain intensity scores. The study is running across roughly 30 U.S. sites, with secondary endpoints spanning sleep, fatigue, neuropathy symptoms, and overall health status.
Strategically, Dogwood is leaning into a high-need, high-failure setting where there are no approved therapies and where prior pain programs have often stalled on placebo response, tolerability, or endpoint durability. The short, intensive dosing schedule and near-term outcome window are designed to simplify operations and reduce variability, while the inclusion of long-standing CINP patients—reported to average five years of symptoms in the interim set—aims to mitigate regression to the mean. The bet is that a tolerable, clinic-delivered regimen, coupled with rigorous diary-based measurement, can deliver a clean signal consistent with FDA chronic pain guidance. The tension is clear: four-week endpoints can be efficient for signal detection but may fall short of the durability expectations regulators and payers will scrutinize in a pivotal program.
For sites, the profile is operationally attractive: low discontinuations reduce data loss, and a two-week dosing window limits prolonged scheduling burdens typical of chronic pain trials. The trade-off is logistics—eight subcutaneous visits in 14 days require tight clinic throughput and patient coordination. ePRO compliance around daily pain diaries remains a critical execution risk and a likely differentiator across sites. CROs and vendors supporting data capture and retention can benefit from the streamlined design, but must maintain vigilance on placebo management practices and consistency in baseline pain stabilization to preserve assay sensitivity. For sponsors across neuropathic pain, an eventual positive outcome could reset assumptions about feasible trial length and dosing intensity in CINP, while putting pressure on programs reliant on longer outpatient regimens with higher attrition.
Key watch items heading into the readout include the absolute effect size versus placebo, responder rates (such as ≥30% pain reduction), consistency across platinum- versus taxane-related neuropathy, and the trajectory beyond week four to gauge durability. Safety will be dissected for injection-site reactions and systemic tolerability to validate the low discontinuation signal. If the Phase 2b result holds, the pivotal design questions will center on extending treatment and follow-up duration, potential incorporation of an active comparator used off-label in CINP management, and strategies to manage placebo response at larger scale. Dogwood’s ability to sustain enrollment velocity, expand its site network without diluting data quality, and lock down robust diary adherence will determine whether an efficient signal can translate into a registrational path in a field that has punished overreach.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
